| Name | Title | Contact Details |
|---|
Tepha is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kindbody is reinventing healthcare for the modern family, starting with fertility, family-building and wellness benefits. Through a national network of locations, Kindbody is bringing together clinical excellence, best-in-class technology, and accessible pricing — connecting the full patient experience in one, intuitive platform.
Pacific Northwest X-Ray Inc is a Gresham, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Baystate Health is an integrated health care delivery system serving a population of nearly one million people in western Massachusetts. We are one of the largest health systems in New England with more than 12,000 employees, four hospitals, and over 80 medical practices. Baystate Medical Center has the only Level 1 Trauma Center in the region, and the only neonatal and pediatric intensive care units. University of Massachusetts Medical School-Baystate is the only regional campus of the University of Massachusetts Medical School. Baystate Medical Center has been ranked as one of the nation`s top hospitals for 2015-2016 by U.S. News & World Report and for the third time, Baystate Medical Center has been named a Magnet™ hospital for excellence in nursing services.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.